Breaking News Instant updates and real-time market news.

INCY

Incyte

$64.02

-19.05 (-22.93%)

07:57
04/09/18
04/09
07:57
04/09/18
07:57

Incyte price target lowered to $76 from $142 at Morgan Stanley

Morgan Stanley analyst Thomas Smith lowered his price target on Incyte to $76 after removing epacadostat from his model following the announcement that the ECHO-301 trial failed to show benefit over PD-1 monotherapy in melanoma. However, Smith believes Incyte shares already reflected a significant amount of investor skepticism heading into the ECHO-301 data and he views the company as having one of the deepest pipelines in SMID-cap biotech, supported by the Jakafi base business in myelofibrosis, Iclusig royalties in Europe and royalties from baricitinib. Smith keeps an Overweight rating on Incyte shares.

  • 23

    Apr

  • 12

    Jun

INCY Incyte
$64.02

-19.05 (-22.93%)

04/09/18
OPCO
04/09/18
NO CHANGE
Target $65
OPCO
Perform
Incyte price target lowered to $65 from $110 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte (INCY) to $65 from $110 following the update on the termination of ECHO-301 after epacadostat failed to show a PFS or OS benefit when combined with Merck's (MRK) Keytruda versus Keytruda alone. While the company plans to conduct subgroup analyses of ECHO-301 looking at various biomarkers such as PD-L1 expression and tumor mutational burden which may provide additional insights, the analyst sees no reason at this time to continue development of epacadostat as he considers it highly unlikely to demonstrate efficacy in other tumor types and/or combinations. Olson reiterates a Perform rating on Incyte's shares.
04/09/18
NOMU
04/09/18
NO CHANGE
Target $102
NOMU
Buy
Incyte price target lowered to $102 from $139 at Nomura Instinet
Nomura Instinet analyst Christopher Marai on Friday lowered his price target for Incyte to $102 after the Phase ECHO-301 trial of epacadostat and pembrolizumab in advanced metastatic melanoma was stopped. The analyst keeps a Buy rating on the shares. He tells investors to focus on the company's TKI pipeline.
04/09/18
RHCO
04/09/18
DOWNGRADE
Target $5
RHCO
Hold
NewLink Genetics downgraded to Hold at SunTrust on Incyte trial failure
As reported late last week, SunTrust analyst Peter Lawson downgraded NewLink Genetics (NLNK) to Hold from Buy and lowered his price target to $5 from $19. Lawson cites the announcement of negative results from the Phase 3 ECHO-301 of epacadostat + Keytruda in melanoma by Incyte (INCY), saying the data also implies a "significant negative read through for NewLink's IDO agent, indoximod". Lawson adds that the results have led him to remove melanoma from his NewLink model and also reduce the probability of success in pancreatic cancer, lowering the probability of adjusted peak sales from $415M to just $11M.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.

TODAY'S FREE FLY STORIES

BDORY

Banco do Brasil

05:04
04/23/18
04/23
05:04
04/23/18
05:04
Downgrade
Banco do Brasil rating change  »

Banco do Brasil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$99.64

-4.57 (-4.39%)

05:02
04/23/18
04/23
05:02
04/23/18
05:02
Upgrade
State Street rating change  »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

KORS

Michael Kors

$65.02

-0.7 (-1.07%)

04:57
04/23/18
04/23
04:57
04/23/18
04:57
Upgrade
Michael Kors rating change  »

Deutsche Bank upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$12.60

-0.47 (-3.60%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Syros Pharmaceuticals management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    May

AVEO

Aveo Oncology

$2.59

-0.05 (-1.89%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Aveo Oncology management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

CIGI

Colliers International

$70.20

0.75 (1.08%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
UBS REITs analyst to hold an analyst/industry conference call »

REITs Analyst Yulico,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 30

    Apr

  • 01

    May

CNAT

Conatus

$3.58

0.02 (0.56%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Conatus management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

KMB

Kimberly-Clark

$100.04

-3.3 (-3.19%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Technical Analysis
Technical Earnings Preview: Kimberly-Clark near 5-year lows ahead of earnings »

The shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 30

    May

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Existing Home Sales to be reported at 10:00 »

March Existing Home Sales…

INFY

Infosys

$17.38

0.21 (1.22%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Infosys to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

MLNX

Mellanox

$75.80

-1.45 (-1.88%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Mellanox management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

APVO

Aptevo Therapeutics

$4.33

0.01 (0.23%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Aptevo Therapeutics management to meet with Piper Jaffray »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

April PMI Composite Flash…

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

IFRX

InflaRx

$38.78

1.67 (4.50%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
InflaRx has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss dental…

LUK

Leucadia

$24.02

-0.1 (-0.41%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Leucadia management to meet with Oppenheimer »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    May

  • 04

    Oct

CNK

Cinemark

$39.66

-0.74 (-1.83%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Cinemark management to meet with MKM Partners »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

CRAY

Cray

$22.40

-0.2 (-0.88%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Cray management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 29

    May

SNX

Synnex

$103.51

-0.33 (-0.32%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Synnex management to meet with Loop Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 03

    May

  • 04

    May

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

March Chicago Fed…

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
UBS leisure/lodging analyst to hold an analyst/industry conference call »

Leisure, Gaming &…

ASND

Ascendis Pharma

$63.83

-1.17 (-1.80%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Ascendis Pharma has a conference call hosted by JPMorgan »

JPMorgan Analyst Fye will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 08

    May

  • 10

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.